{"filing":{"accession_number":"0001193125-26-331381","cik":"0001676725","ticker":"IDYA","company_name":"IDEAYA Biosciences, Inc.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"idya-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526331381/idya-20260804.htm"},"events":[{"id":23502,"run_id":21246,"accession_number":"0001193125-26-331381","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a standard earnings release disclosing IDEAYA's financial results for Q2 2026 (ended June 30, 2026), including collaboration revenue of $8.9 million, R\u0026D expenses of $108.7 million, G\u0026A expenses of $22.5 million, and a net loss of $112.5 million. The filing is furnished under Item 2.02 (Results of Operations and Financial Condition) with the full press release attached as Exhibit 99.1, which is the typical structure for quarterly earnings disclosures. The release also includes material business updates on clinical trial progress and cash position ($1.24 billion), making it material to investors.","company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":23747,"accession_number":"0001193125-26-331381","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing IDEAYA's financial results for Q2 2026 (ended June 30, 2026), including collaboration revenue of $8.9 million, R\u0026D expenses of $108.7 million, G\u0026A expenses of $22.5 million, and a net loss of $112.5 million. The filing is furnished under Item 2.02 (Results of Operations and Financial Condition) with the full press release attached as Exhibit 99.1, which is the typical structure for quarterly earnings disclosures. The release also includes material business updates on clinical trial progress and cash position ($1.24 billion), making it material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T10:09:40.827583+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23747,"accession_number":"0001193125-26-331381","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing IDEAYA's financial results for Q2 2026 (ended June 30, 2026), including collaboration revenue of $8.9 million, R\u0026D expenses of $108.7 million, G\u0026A expenses of $22.5 million, and a net loss of $112.5 million. The filing is furnished under Item 2.02 (Results of Operations and Financial Condition) with the full press release attached as Exhibit 99.1, which is the typical structure for quarterly earnings disclosures. The release also includes material business updates on clinical trial progress and cash position ($1.24 billion), making it material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T10:09:40.827583+00:00","company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","filing_date":"2026-08-04"}]}